|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SERPINB9 |
Gene summary for SERPINB9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SERPINB9 | Gene ID | 5272 |
| Gene name | serpin family B member 9 | |
| Gene Alias | CAP-3 | |
| Cytomap | 6p25.2 | |
| Gene Type | protein-coding | GO ID | GO:0001906 | UniProtAcc | A0A024QZT4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5272 | SERPINB9 | AEH-subject1 | Human | Endometrium | AEH | 5.25e-49 | 1.05e+00 | -0.3059 |
| 5272 | SERPINB9 | AEH-subject2 | Human | Endometrium | AEH | 8.31e-27 | 8.67e-01 | -0.2525 |
| 5272 | SERPINB9 | AEH-subject3 | Human | Endometrium | AEH | 3.38e-17 | 5.76e-01 | -0.2576 |
| 5272 | SERPINB9 | AEH-subject4 | Human | Endometrium | AEH | 3.76e-15 | 6.40e-01 | -0.2657 |
| 5272 | SERPINB9 | AEH-subject5 | Human | Endometrium | AEH | 4.35e-06 | 2.57e-01 | -0.2953 |
| 5272 | SERPINB9 | EEC-subject1 | Human | Endometrium | EEC | 2.42e-12 | 5.16e-01 | -0.2682 |
| 5272 | SERPINB9 | EEC-subject2 | Human | Endometrium | EEC | 2.45e-18 | 5.56e-01 | -0.2607 |
| 5272 | SERPINB9 | EEC-subject3 | Human | Endometrium | EEC | 2.86e-05 | 4.01e-01 | -0.2525 |
| 5272 | SERPINB9 | EEC-subject4 | Human | Endometrium | EEC | 5.60e-11 | 4.41e-01 | -0.2571 |
| 5272 | SERPINB9 | EEC-subject5 | Human | Endometrium | EEC | 5.55e-07 | 3.25e-01 | -0.249 |
| 5272 | SERPINB9 | C04 | Human | Oral cavity | OSCC | 4.84e-03 | 1.25e-01 | 0.2633 |
| 5272 | SERPINB9 | C21 | Human | Oral cavity | OSCC | 1.74e-08 | 4.84e-01 | 0.2678 |
| 5272 | SERPINB9 | C30 | Human | Oral cavity | OSCC | 2.55e-04 | 1.31e-01 | 0.3055 |
| 5272 | SERPINB9 | C06 | Human | Oral cavity | OSCC | 4.94e-03 | 6.25e-01 | 0.2699 |
| 5272 | SERPINB9 | LN46 | Human | Oral cavity | OSCC | 3.49e-06 | 3.64e-01 | 0.1666 |
| 5272 | SERPINB9 | EOLP-1 | Human | Oral cavity | EOLP | 3.59e-12 | 5.69e-01 | -0.0202 |
| 5272 | SERPINB9 | EOLP-2 | Human | Oral cavity | EOLP | 3.38e-12 | 4.12e-01 | -0.0203 |
| 5272 | SERPINB9 | NEOLP-2 | Human | Oral cavity | NEOLP | 3.31e-03 | 2.45e-01 | -0.0196 |
| 5272 | SERPINB9 | NEOLP-3 | Human | Oral cavity | NEOLP | 4.32e-04 | 3.19e-01 | -0.0191 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004440316 | Endometrium | AEH | biological process involved in symbiotic interaction | 70/2100 | 290/18723 | 3.26e-10 | 3.55e-08 | 70 |
| GO:005170116 | Endometrium | AEH | biological process involved in interaction with host | 53/2100 | 203/18723 | 2.48e-09 | 1.93e-07 | 53 |
| GO:005254716 | Endometrium | AEH | regulation of peptidase activity | 85/2100 | 461/18723 | 2.47e-06 | 7.11e-05 | 85 |
| GO:005254816 | Endometrium | AEH | regulation of endopeptidase activity | 76/2100 | 432/18723 | 4.42e-05 | 7.43e-04 | 76 |
| GO:004328116 | Endometrium | AEH | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 43/2100 | 209/18723 | 5.77e-05 | 9.10e-04 | 43 |
| GO:004586116 | Endometrium | AEH | negative regulation of proteolysis | 63/2100 | 351/18723 | 1.07e-04 | 1.53e-03 | 63 |
| GO:200011616 | Endometrium | AEH | regulation of cysteine-type endopeptidase activity | 46/2100 | 235/18723 | 1.14e-04 | 1.62e-03 | 46 |
| GO:005134610 | Endometrium | AEH | negative regulation of hydrolase activity | 65/2100 | 379/18723 | 3.18e-04 | 3.57e-03 | 65 |
| GO:00518174 | Endometrium | AEH | modulation of process of other organism involved in symbiotic interaction | 19/2100 | 81/18723 | 1.32e-03 | 1.12e-02 | 19 |
| GO:00026838 | Endometrium | AEH | negative regulation of immune system process | 69/2100 | 434/18723 | 1.76e-03 | 1.41e-02 | 69 |
| GO:00358216 | Endometrium | AEH | modulation of process of other organism | 21/2100 | 106/18723 | 6.61e-03 | 3.90e-02 | 21 |
| GO:001046610 | Endometrium | AEH | negative regulation of peptidase activity | 43/2100 | 262/18723 | 6.78e-03 | 3.95e-02 | 43 |
| GO:004440317 | Endometrium | EEC | biological process involved in symbiotic interaction | 73/2168 | 290/18723 | 7.47e-11 | 9.95e-09 | 73 |
| GO:005170117 | Endometrium | EEC | biological process involved in interaction with host | 54/2168 | 203/18723 | 2.67e-09 | 2.01e-07 | 54 |
| GO:005254717 | Endometrium | EEC | regulation of peptidase activity | 91/2168 | 461/18723 | 2.00e-07 | 8.93e-06 | 91 |
| GO:004586117 | Endometrium | EEC | negative regulation of proteolysis | 72/2168 | 351/18723 | 8.46e-07 | 2.98e-05 | 72 |
| GO:005254817 | Endometrium | EEC | regulation of endopeptidase activity | 82/2168 | 432/18723 | 3.96e-06 | 1.04e-04 | 82 |
| GO:004328117 | Endometrium | EEC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 46/2168 | 209/18723 | 1.20e-05 | 2.46e-04 | 46 |
| GO:005134615 | Endometrium | EEC | negative regulation of hydrolase activity | 72/2168 | 379/18723 | 1.46e-05 | 2.87e-04 | 72 |
| GO:200011617 | Endometrium | EEC | regulation of cysteine-type endopeptidase activity | 49/2168 | 235/18723 | 2.91e-05 | 5.08e-04 | 49 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa051466 | Endometrium | AEH | Amoebiasis | 29/1197 | 102/8465 | 1.22e-04 | 1.10e-03 | 8.06e-04 | 29 |
| hsa0514613 | Endometrium | AEH | Amoebiasis | 29/1197 | 102/8465 | 1.22e-04 | 1.10e-03 | 8.06e-04 | 29 |
| hsa0514622 | Endometrium | EEC | Amoebiasis | 28/1237 | 102/8465 | 5.23e-04 | 3.83e-03 | 2.85e-03 | 28 |
| hsa0514632 | Endometrium | EEC | Amoebiasis | 28/1237 | 102/8465 | 5.23e-04 | 3.83e-03 | 2.85e-03 | 28 |
| hsa051468 | Oral cavity | OSCC | Amoebiasis | 59/3704 | 102/8465 | 2.78e-03 | 7.17e-03 | 3.65e-03 | 59 |
| hsa0514615 | Oral cavity | OSCC | Amoebiasis | 59/3704 | 102/8465 | 2.78e-03 | 7.17e-03 | 3.65e-03 | 59 |
| hsa0514623 | Oral cavity | EOLP | Amoebiasis | 26/1218 | 102/8465 | 2.09e-03 | 7.03e-03 | 4.15e-03 | 26 |
| hsa0514633 | Oral cavity | EOLP | Amoebiasis | 26/1218 | 102/8465 | 2.09e-03 | 7.03e-03 | 4.15e-03 | 26 |
| hsa0514641 | Oral cavity | NEOLP | Amoebiasis | 26/1112 | 102/8465 | 5.36e-04 | 3.05e-03 | 1.92e-03 | 26 |
| hsa0514651 | Oral cavity | NEOLP | Amoebiasis | 26/1112 | 102/8465 | 5.36e-04 | 3.05e-03 | 1.92e-03 | 26 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SERPINB9 | SNV | Missense_Mutation | c.190N>A | p.Glu64Lys | p.E64K | P50453 | protein_coding | tolerated(0.42) | benign(0.005) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| SERPINB9 | SNV | Missense_Mutation | rs770929943 | c.989N>T | p.Ala330Val | p.A330V | P50453 | protein_coding | tolerated(0.06) | benign(0.226) | TCGA-EW-A2FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | goserelin | SD |
| SERPINB9 | SNV | Missense_Mutation | c.14N>T | p.Ser5Phe | p.S5F | P50453 | protein_coding | tolerated(0.09) | probably_damaging(0.961) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| SERPINB9 | insertion | Frame_Shift_Ins | novel | c.141_142insCCCAACATCTCTACTAAAAATACAAAAATTAGCCAGGT | p.Gly48ProfsTer26 | p.G48Pfs*26 | P50453 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| SERPINB9 | insertion | Nonsense_Mutation | novel | c.198_199insGGTCTCAAGTGATCCTCCTGCCTGTTGGGATTACAGATGTGAGC | p.His67GlyfsTer4 | p.H67Gfs*4 | P50453 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SERPINB9 | insertion | Frame_Shift_Ins | novel | c.568_569insCCTCT | p.Glu190AlafsTer10 | p.E190Afs*10 | P50453 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| SERPINB9 | SNV | Missense_Mutation | c.14C>G | p.Ser5Cys | p.S5C | P50453 | protein_coding | tolerated(0.3) | benign(0.123) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SERPINB9 | SNV | Missense_Mutation | c.95N>A | p.Pro32His | p.P32H | P50453 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERPINB9 | SNV | Missense_Mutation | c.487N>G | p.Asn163Asp | p.N163D | P50453 | protein_coding | deleterious(0.01) | possibly_damaging(0.603) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERPINB9 | SNV | Missense_Mutation | rs555422802 | c.215C>T | p.Ser72Leu | p.S72L | P50453 | protein_coding | tolerated(0.15) | benign(0.013) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |